Search PubMed⌕ Search

Biomedical subjects

S Baggio

Publications and source records attributed to S Baggio.

7 recordsLinked to original sources
PubMed2001

catena-Poly[[diaqua(1,10-phenanthrolone-N,N')manganese(II)]-mu-(thiosulfato-O:S] and bis(2,2'-bi-pyridyl-N,N')(tetrathionato-O,O')-manganese(II).

The structures of [Mn(S2O3)2(C12H8N2)(H2O(2)] and [Mn(S4O6)(C10H8N2)(2)] are presented. The former consists of pairs of polymeric chains formed by manganese polyhedra bridged by bidentate thiosulfate anions, which are in turn related to each other by a pseudo-twofold screw axis. The latter has crystallographic twofold symmetry and consists of monomers in which manganese displays its typical octahedral coordination provided by the bidentate bites of two bipyridine bases and a tetrathionate anion, which is, to our knowledge, the first chelating tetrathionate to be reported in the literature.

Journal Article↗
PubMed2000

catena-Poly

Explore the source record for details and available documents.

Journal Article↗
PubMed2000

Bis(1,10-phenanthroline-N,N')(thiosulfato-O, S)nickel(II)-water-methanol (1/0.92/1.4) and bis(2,2'-bipyridyl-N, N')(thiosulfato-O,S)nickel(II)-water-methanol (1/2/0.55)

The title compounds, [Ni(S(2)O(3))(C(12)H(8)N(2))(2)].0.92H(2)O.1. 4CH(4)O and [Ni(S(2)O(3))(C(10)H(8)N(2))(2)].2H(2)O.0.55CH(4)O, are monomeric, containing nickel(II) in a distorted octahedral coordination environment provided by the four N atoms of two bidentate bipy or phen groups and one S and one O atom from a chelating thiosulfate anion. The crystals are highly unstable outside their mother liquors and are stabilized in solution by a not fully determined number of water and methanol solvate molecules. The phenanthroline structure includes two independent moieties related by a non-crystallographic inversion center. The thiosulfate anions display the usual S-O lengthening found when the anion acts in a bidentate mode.

Journal Article↗
PubMed1991

[Efficacy and tolerance of LA 50 mg nicardipine in hypertensive athletes].

The beneficial effects of physical exercise on the blood pressure are widely recognised. Nevertheless, some athletes remain hypertensive and the treatment of this population makes special demands with respect to treatment efficacy and tolerability, the respect of athletic performance and problems of proscribed substances. For example, the Athletic Boards have prohibited betablockers and diuretics in competitive athletes. The aim of this study was to assess nicardipine LA 50 mg administered twice daily in the special context of hypertensive athletes. Thirty-eight athletes with mild or moderate hypertension undergoing endurance training were included in this double blind trial versus placebo. After two months treatment, the systolic and diastolic blood pressures were significantly lower at rest in the nicardipine than in the placebo group (delta SBP = -18.9 vs -4.1 mmHg, p less than 0.001; delta DBP = -15.7 vs -4.1 mmHg, p less than 0.01). In addition the maximum SBP on effort was significantly lower in the nicardipine group (200 vs 215 mmHg, p less than 0.05). On the other hand, no difference was observed between the two groups as regards the maximum oxygen consumption (delta VO2 max = 6.2 vs -0.4 ml/min/kg, NS) and duration of effort (13.75 vs 12.32 min, NS), showing that athletic performance was unchanged in the group treated by nicardipine LA. These results suggest that treatment with nicardipine LA fulfills the special criteria of hypertensive athletes.

Adult↗